Compare CDMOs in the broader Asia Pacific region including Australia and New Zealand. Filter by regulatory approvals, manufacturing type, and therapeutic expertise.
The Asia Pacific pharmaceutical manufacturing landscape extends beyond the major Asian markets to include Australia, New Zealand, and Pacific island nations. Australia in particular has a growing CDMO sector, driven by TGA regulatory expertise, government incentives for domestic manufacturing, and proximity to Southeast Asian markets.
Australia's pharmaceutical manufacturing is concentrated in Melbourne and Sydney. The country offers strong regulatory alignment (TGA is recognized by the FDA and EMA through mutual recognition agreements), well-trained workforce, and government grants for pharmaceutical R&D and manufacturing. CDMOs here serve both domestic and export markets, particularly for clinical-stage biologics and specialty drug products.
For pharma companies targeting Asian market access, Asia Pacific CDMOs can provide local manufacturing presence that simplifies regulatory submissions and supply chain logistics for Australia, New Zealand, and ASEAN markets.
No companies found in this category yet. Check back soon.
Browse all CDMOsOur AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.